Supernus Pharmaceuticals SUPN Net debt / EBITDA

Net debt / EBITDA at other companies

AbbVieABBV

2.5×—

Acadia PharmaceuticalsACAD

-3.2×-4.7×

Neurocrine BiosciencesNBIX

0.2×-0.3×

XER

Xeris Biopharma Holdings, Inc.XERS

4.4×—

Zevra Therapeutics, Inc.ZVRA

-1.6×—

Collegium Pharmaceutical, Inc.COLL

-0.5×+0.3×

FAQ

What is Supernus Pharmaceuticals's net debt / EBITDA?

Supernus Pharmaceuticals (SUPN) reported net debt / EBITDA of -3.9× in Q1 2026.

How has Supernus Pharmaceuticals's net debt / EBITDA changed year-over-year?

Supernus Pharmaceuticals's net debt / EBITDA decreased by 628.3% year-over-year, from -0.5× to -3.9×.

What is the long-term trend for Supernus Pharmaceuticals's net debt / EBITDA?

Over 5 years (2020 to 2025), Supernus Pharmaceuticals's net debt / EBITDA has grown at a 20.6% compound annual growth rate (CAGR), from -1.2× to -3×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.